Business Wire

CA-CEPTON-TECHNOLOGIES

11.11.2021 15:02:12 CET | Business Wire | Press release

Share
Cepton’s Nova Lidar Named as CES 2022 Innovation Awards Honoree

Cepton Technologies, Inc. announced today that it has been named a CES® 2022 Innovation Awards Honoree in the Vehicle Intelligence & Transportation category for its Nova lidar , a miniature, wide field of view lidar sensor for near-range applications. The announcement was made ahead of CES 2022 , a global consumer electronics and consumer technology trade show that will be held from January 5-8 in Las Vegas, NV and digitally.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211111005540/en/

The CES Innovation Awards program, owned and produced by the Consumer Technology Association (CTA)® , is an annual competition honoring outstanding design and engineering in 27 consumer technology product categories. An elite panel of industry expert judges , including members of the media, designers, engineers and more, reviewed submissions based on innovation, engineering and functionality, aesthetic and design. The Nova lidar has been selected among a record high number of submissions to this year’s program, signifying the weight of Nova’s technology and design value for the automotive market.

Nova features a miniature form factor and a wide field of view, making it ideally suited for seamless integration into modern vehicles. With a target volume price point under $100, Nova sets a worldwide benchmark with its unprecedented combination of compactness, field of view coverage and targeted affordability.

Nova is designed to help minimize perception blind spots to enhance advanced driver assistant systems (ADAS) and autonomous driving (AD) capabilities.

It aims to address major gaps in proximity detection of objects with current sensor technologies such as cameras, radars and ultrasonic sensors. Powered by Cepton’s patented Micro Motion Technology (MMT® ) , Nova enables high-resolution 3D imaging to accurately detect small children, on-road objects, protrusions and road edges etc. to help increase vehicle safety and enable a higher level of autonomy. Compared to some other near-range lidars , Nova achieves a higher field of view in both horizontal (120°) and vertical (60°) directions with significantly lower size, power and weight.

Benefiting from the maturity of MMT and Cepton’s proprietary lidar engine ASIC for advanced signal processing, Nova is built to meet the stringent requirements of the automotive industry. An automotive-grade lidar , it supports ASIL-B functional safety and consumes <3.5 W (typical power). Nova can be elegantly embedded all around an automobile to provide a complete 360° view of a vehicle’s immediate surroundings, without disrupting the vehicle’s design aesthetics.

In addition to automotive applications, Nova can also enable autonomous robotics and ground vehicles for industrial applications.

Earlier this year, Nova was a second-place award winner at the 2021 Tech.AD Europe Awards , in the category of Most Innovative Use of Artificial Intelligence & Machine Learning in the Development of Autonomous Vehicles & Respective Technologies.

“The key value proposition of the Nova lidar is its combination of a wide horizontal and vertical field of view, the very compact size, the low power consumption and an attractive volume price,” said Dr. Jun Pei, CEO of Cepton.

“With that, we hope to significantly enhance vehicle safety in everyday passenger cars by making Nova a mass-market lidar solution . In addition, it uses a scaled version of Cepton’s patented MMT architecture that is already in use in the long-range lidars that we are supplying in our major ADAS lidar program with our key OEM customer . We believe that this means that the core technology enabling Nova has reached a high maturity level and is licensable to manufacturing partners, especially automotive Tier 1s .”

Detailed information about the CES 2022 Innovation Awards honorees can be found at CES.tech/innovation . In January 2022, Cepton will join many other honorees in showcasing their products in the Innovation Awards Showcase area at CES 2022. At the Cepton Booth (#5518, LVCC – West Hall), Cepton will also showcase Nova alongside its comprehensive portfolio of lidar solutions for smart mobility , covering automotive and smart infrastructure applications . Please visit the Cepton website for more information.

About Cepton Technologies, Inc.

Cepton provides state-of-the-art, intelligent, lidar-based solutions for a range of markets such as automotive (ADAS/AV), smart cities , smart spaces and smart industrial applications. Cepton’s patented MMT®-based lidar technology enables reliable, scalable and cost-effective solutions that deliver long range, high resolution 3D perception for smart applications.

Founded in 2016 and led by industry veterans with over two decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high performance, high quality lidar solutions. Cepton is headquartered in San Jose, California, USA, with a presence in Germany, Canada, Japan, India and China, to serve a fast-growing global customer base. For more information, visit www.cepton.com and follow us on Twitter and LinkedIn .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye